CombiMatrix' Shares Down 7 Percent on Q4 Revenue Slide | GenomeWeb
NEW YORK (GenomeWeb News) — Shares in CombiMatrix were down 7 percent at $.76 in mid-afternoon trading after the company this morning reported dismal fourth-quarter results.
As GenomeWeb News reported this morning, the Acacia unit said fourth-quarter revenues fell 76 percent and losses more than doubled year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.